Intellia Therapeutics and Regeneron Pharmaceuticals entered into a co-development and co-promotion agreement for the drug nex-z, with revenues tied to cost reimbursements.
2 reports, 2 independent
Updated Aug 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Intellia Therapeutics and Regeneron Pharmaceuticals entered into a co-development and co-promotion agreement for the drug nex-z, with revenues tied to cost reimbursements.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
Nothing else this week.
-
Regeneron Pharmaceuticals
American pharmaceutical company
Coverage
Newest first; wire copies grouped- ZacksIntellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus Intellia Therapeutics NTLA reported second-quarter 2025 loss of 99 cents per share (including one-time expenses of change in fair v
- GlobeNewswireIntellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR w